{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-016793","form_type":"8-K","ticker":"ZVSA","cik":"0001859007","company_name":"ZyVersa Therapeutics, Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.318883+00:00","generated_at":"2026-06-15T01:37:50.745615+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ZyVersa Q1 2023 net loss $3.5M; cash only $1.3M, needs financing","bullets":["Cash of $1.3M as of March 31, 2023, sufficient only on month-to-month basis; company requires additional financing.","Net loss of $3.5M for Q1 2023 improved $0.2M vs Q1 2022 net loss of $3.7M, aided by $1.0M deferred tax benefit.","G&A expenses rose 53.7% to $3.5M due to insurance, marketing, and PIPE failure payments.","VAR 200 investigator-initiated trial expected Q4 2023; IND submission for IC 100 anticipated Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-016793","json":"https://secwatch.observer/filing/0001493152-23-016793.json","markdown":"https://secwatch.observer/filing/0001493152-23-016793.md","text":"https://secwatch.observer/filing/0001493152-23-016793.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223016793/0001493152-23-016793-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223016793/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:37:50.745615+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"15fd0cb560b018fc57ef86ccefd7ccfa552f6a10","claim":"ZyVersa Therapeutics, Inc. reported the first quarter of 2023 ending March 31, 2023 results: net income approximately $3.5 million.","evidence_excerpt":"Net losses were approximately $3.5 million for the three months ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223016793/0001493152-23-016793-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2023 ending March 31, 2023"},{"label":"Net income","value":"approximately $3.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}